Table 1.

Demographic and Clinical Characteristics of the Study Group at the Start of Dasatinib Therapy

Characteristic	Total (N = 62)		Twice-Daily Treatment (n = 31)		Once-Daily Treatment (n = 31)		P
	Median	Range	Median	Range	Median	Range
Age, years	47	18-76	46	18-70	47	22-76	.72
Splenomegaly							.79
No. of patients	21		10		11
%	34		32		35
Hemoglobin, g/dL	11.9	6.7-14.9	11.7	6.7-14.8	12.0	8.4-14.9	.15
WBC, × 109/L	22.2	0.8-193	13.5	0.8-112.1	37.3	4.4-193	.01
Platelets, × 109/L	315	94-1,906	278	131-1,769	384	94-1,906	.36
Peripheral blood blasts, %	0	0-5	0	0-3	0	0-5	.33
Peripheral blood basophils, %	3	0-17	4	0-18	3	0-17	.27
Bone marrow blasts, %	2	0-8	2	0-6	2	0-8	.86
Bone marrow basophils, %	3	0-12	3	0-12	2	0-6	.11
Sokal risk group							.75
Low
No. of patients	50		26		24
%	81		84		77
Intermediate
No. of patients	8		3		5
%	13		10		16
High
No. of patients	4		2		2
%	6		6		6
Ph-positive metaphases at start of therapy, %	100	10-100	100	10-100	100	81-100	.37
Clonal evolution							.97
No. of patients	4		2		2
%	7		6		6